Klinička farmacija i terapija: prema drugome engleskom izdanju. by Roger Walker, Velimir Božikov. Unknown, Pages, Published ISBN Klinicka – Free download as PDF File .pdf), Text File .txt) or read online for rešavanje terapijskih problema pacijenta, praćenje ishoda terapije. Klinička farmacija i terapija, (prevod udžbenika Clinical Pharmacy and. Therapeutics, 2nd edition), Urednici: R. Walker, C. Edwards, Školska knjiga,. Zagreb.
|Published (Last):||24 January 2014|
|PDF File Size:||18.80 Mb|
|ePub File Size:||17.54 Mb|
|Price:||Free* [*Free Regsitration Required]|
Cardiologia Croatica, 13 MicroRNA in kidney disease. MicroRNAs in kidney disease: Am J Kidney Dis.
Mechanisms of post-transcriptional regulation by microRNAs: Many roads to maturity: MicroRNAs in heart failure: Eur J Heart Fail. Denby L, Baker AH. Targeting non-coding RNA for the therapy of renal disease.
Data STATUS | Medicina
Lakhia R, Patel V. J R Coll Physicians Edinb.
MicroRNAs as potential therapeutic targets in kidney disease. J Formos Med Assoc.
N Engl J Med. Development of microRNA therapeutics is coming of age. Kumar P, Clark M, Eds.
Farmacija – Wikipedia
Prevalence of chronic terappija disease: Hrvatski zavod za javno zdravstvo. Soliman S, Mohan C. Akkina S, Becker BN. MicroRNAs in kidney function and disease. MicroRNAs in kidney physiology and disease.
Klinička farmacija i terapija : prema drugome engleskom izdanju
Ma L, Qu L. The function of microRNAs in renal development and pathophysiology.
Riboregulators in kidney development and function. MicroRNAs in renal fibrosis. Serum microRNAs are altered in various stages of chronic kidney disease: Micro-RNA expression in the urinary sediment of patients with chronic kidney diseases.
Thioesterase-mediated control of cellular calcium homeostasis enables hepatic ER stress. Camm A, Bunce N.
Non-cardiomyocyte microRNAs in heart failure. MicroRNAs as a diagnostic tool for heart failure and atrial fibrillation. Int J Mol Sci. MiRp as a circulating biomarker for heart failure. Circulating faemacija as candidate markers to distinguish heart failure in breathless patients. Signature of circulating microRNAs in patients with acute heart failure. Comparative RNA-sequencing analysis of myocardial and circulating small RNAs in human heart failure and their utility as biomarkers. Serum levels of microRNAs in patients with heart failure.
MicroRNA signatures in peripheral blood mononuclear cells of chronic heart failure patients. Multivariate miRNA signatures as biomarkers for non-ischaemic systolic heart failure. MicroRNA signatures differentiate preserved from reduced ejection fraction heart failure. Circulating microRNAs in heart failure with reduced and preserved left ventricular ejection fraction. Therapeutic cardiac-targeted delivery of miR-1 reverses pressure overload-induced cardiac hypertrophy and attenuates pathological remodeling.
J Am Heart Assoc.
MicroRNA controls cardiac hypertrophy. Int J Biochem Cell Biol. Arterioscler Thromb Vasc Biol.